Thalidomide improves cetuximab and chemotherapy effectiveness for left colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine if thalidomide can enhance the effectiveness of cetuximab when combined with standard chemotherapy for patients with stage IV RAS and BRAF wild-type unresectable left colorectal cancer. The trial will evaluate changes in cytokines and their potential impact on the efficacy of the treatment regimen. By assessing these factors, the study seeks to provide a foundation for future research and clinical applications in targeted therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with RAS and BRAF wild-type IV unresectable left colorectal cancer confirmed by pathology and tissue/cytology and genetic testing;
2. Physical state is good: PS 0-2;
3. Expected survival of more than 3 months;
4. Aged 18-75 years old;
5. Have not received systematic chemotherapy before;
6. Did not receive cetuximab treatment;
7. Liver, kidney and bone marrow functions are basically normal;
8. The clearance period of chemotherapy and molecular targeted therapy is more than 4 weeks;
9. Voluntary participation in the group, good compliance, can cooperate with the experiment observation, and sign the written informed consent.

Exclusion Criteria:

1. Patients with severe dysfunction of vital organs (heart, liver, kidney);
2. Patients with other malignant tumors;
3. Patients who are pregnant or breastfeeding (women of childbearing age need to check pregnancy test);
4. In the active phase of acute or chronic infectious diseases;
5. People with a clear history of drug allergy or allergic constitution;
6. Patients participating in other clinical trials;
7. Other conditions in which the patient was considered inappropriate to participate in the study.

Where it's running

• the second affiliated hospital of Army medical university
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Principal investigator: rui kong, doctor — Chongqing Medical University
• Study coordinator: Jianguo Sun, doctor
• Email: sunjianguo@tmmu.edu.cn
• Phone: 023-68774490

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer

  In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07882888

• Cetuximab bioequivalence test in healthy men

  This study tests whether a cetuximab injection is bioequivalent to Erbitux in healthy men to see if they behave the same in the body.

  Recruiting Phase 1 HC Biopharma Inc. · Haikou, Hainan · NCT07813468

• HSK42360-Na tablets with cetuximab in BRAF V600-mutant metastatic colorectal cancer

  This Phase 1/2 study tests whether HSK42360-Na tablets with cetuximab, with or without standard chemotherapy, are safe and may help people whose colorectal cancer has a BRAF V600 mutation that has spread.

  Recruiting Phase 1/2 Haisco Pharmaceutical Group Co., Ltd. · Beijing · NCT07790510

• Neoadjuvant therapy with encorafenib plus cetuximab N01 and mFOLFOX6 in locally advanced BRAF V600E-mutant colorectal cancer

  This trial tests a targeted, pre-surgery treatment to see if it improves the chance of long-term control in adults with locally advanced BRAF V600E-mutant colorectal cancer.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT07789210

• Petosemtamab plus chemotherapy vs standard chemo plus cetuximab or bevacizumab in RAS/BRAF WT colorectal cancer

  This phase 3 trial tests whether adding petosemtamab to standard chemotherapy works better than the usual chemo plus cetuximab or bevacizumab for people with recurrent, unresectable, or metastatic colorectal cancer that is KRAS/NRAS/BRAF wild type.

  Recruiting at 5 sites Phase 3 Genmab · Hot Springs, Arkansas and 4 other locations · NCT07775287

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.